Erytech’s Solid Tumor Hopes Falter As Eryaspase Fails In Phase III Pancreatic Cancer Trial
Erytech’s eryaspase has failed in its Phase III TRYbeCA-1 trial for second-line pancreatic cancer despite analyst excitement for the solid tumor indication. Its attentions now turn, once again, to its acute lymphoblastic leukemia indication.
You may also be interested in...
Rafael’s lead drug candidate has failed in a Phase III trial for pancreatic cancer and the company has been advised to stop a Phase III study of the product in AML.
It has taken almost two decades but it looks as though Erytech could get approval for eryaspase in the US in two indications next year – acute lymphoblastic leukemia and pancreatic cancer.
The French biotech's shares have sunk 30% but Erytech's decision to withdraw its European marketing authorization application for Graspa in the crowded acute lymphoblastic leukemia market, and focus solely on solid tumors, has gone down well with analysts.